keyword
MENU ▼
Read by QxMD icon Read
search

Duloxetine

keyword
https://www.readbyqxmd.com/read/29306690/differential-change-on-depressive-symptom-factors-with-antidepressant-medication-and-cognitive-behavior-therapy-for-major-depressive-disorder
#1
Boadie W Dunlop, Steven P Cole, Charles B Nemeroff, Helen S Mayberg, W Edward Craighead
BACKGROUND: Major depressive disorder (MDD) is a heterogeneous condition and individual patients are likely to be differentially responsive to specific treatments. In an exploratory factor analysis of three rating scales, the Genome-based Therapeutic Drugs for Depression (GENDEP) trial identified three factors that were differentially associated with outcome to nortriptyline and escitalopram. However, this factor analysis has neither been replicated or applied to a psychotherapy treatment...
December 27, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29244076/reference-brain-blood-concentrations-of-citalopram-duloxetine-mirtazapine-and-sertraline
#2
Michael Nedahl, Sys Stybe Johansen, Kristian Linnet
Postmortem blood samples may not accurately reflect antemortem drug concentrations, as the levels of some drugs increase due to postmortem redistribution (PMR). The brain has been suggested as an alternative sampling site. The anatomically secluded site of the brain limits redistribution and prolongs the detection window, thereby enabling sampling from deceased individuals where blood is no longer suitable for analysis. We report concentrations in brain tissue and blood from 91 cases for the four antidepressants citalopram, duloxetine, mirtazapine and sertraline...
December 13, 2017: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/29238391/functional-impairment-and-painful-physical-symptoms-in-patients-with-major-depressive-disorder-treated-with-antidepressants-real-world-evidence-from-the-middle-east
#3
Jihyung Hong, Diego Novick, Maria Victoria Moneta, Ahmed El-Shafei, Héctor Dueñas, Josep Maria Haro
Background: The Global Burden of Disease 2010 study reported the relative size of major depressive disorder (MDD) burden to be greater in the Middle East and North Africa than anywhere else. However, little research has been carried out to examine the comparative effectiveness of antidepressants in this region. Objective: To assess and compare functioning levels in Middle Eastern patients with MDD treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI), and to examine the impacts of depression-related pain on functioning by the type of treatment...
2017: Clinical Practice and Epidemiology in Mental Health: CP & EMH
https://www.readbyqxmd.com/read/29235884/cost-per-successfully-treated-patient-for-vortioxetine-versus-duloxetine-in-adults-with-major-depressive-disorder-an-analysis-of-the-complete-symptoms-of-depression-and-functional-outcome
#4
Michael Cronquist Christensen, Vicki Munro
OBJECTIVE: To determine the cost-effectiveness of vortioxetine versus duloxetine in adults with moderate to severe major depressive disorder (MDD) in Norway using a definition of a successfully treated patient (STP) that incorporates improvement in both mood symptoms and functional capacity. METHODS: Using the population of patients who completed the 8-week CONNECT study, the cost-effectiveness of vortioxetine (n = 168) (10-20 mg/day) versus duloxetine (n = 176) (60 mg/day) was investigated for the treatment of adults in Norway with moderate to severe MDD and self-reported cognitive dysfunction over an 8-week treatment period...
December 13, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29228247/a-randomized-double-blind-placebo-and-active-comparator-controlled-phase-i-study-of-analgesic-antihyperalgesic-properties-of-asp8477-a-fatty-acid-amide-hydrolase-inhibitor-in-healthy-female-subjects
#5
Klaus Schaffler, Ashraf Yassen, Peter Reeh, Paul Passier
Objectives: To evaluate the analgesic/antihyperalgesic effect of ASP8477. Design: Randomized, double-blind, double-dummy, cross-over, placebo- and active comparator-controlled study. Setting: HPR Dr. Schaffler GmbH, Munich, Germany. Subjects: Healthy female subjects aged 18-65 years. Methods: Eligible subjects were randomly assigned to one of six treatment sequences and received multiple ascending doses of ASP8477, duloxetine, and placebo over three treatment periods (each consisting of 21-day dosing separated by 14-day washout periods)...
December 8, 2017: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/29206213/duloxetine-protects-against-oxaliplatin-induced-neuropathic-pain-and-spinal-neuron-hyperexcitability-in-rodents
#6
Woojin Kim, Yeongu Chung, Seunghwan Choi, Byung-Il Min, Sun Kwang Kim
Oxaliplatin is a widely used chemotherapy agent, but induces serious peripheral neuropathy. Duloxetine is a dual reuptake inhibitor of serotonin and norepinephrine, and is shown to be effective against pain. However, whether and how duloxetine can attenuate oxaliplatin-induced allodynia in rodents is not clearly understood. A single injection of oxaliplatin (6 mg/kg, intraperitoneal; i.p.) induced a cold and mechanical allodynia, which was assessed by acetone and von Frey filament tests, respectively. When significant allodynic signs were observed, three different doses of duloxetine (10, 30, and 60 mg/kg, i...
December 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29203420/compound-action-potential-inhibition-produced-by-various-antidepressants-in-the-frog-sciatic-nerve
#7
Ryo Hirao, Tsugumi Fujita, Aiko Sakai, Eiichi Kumamoto
Although an inhibition of action potential conduction in nerve fibers possibly contributes to at least a part of antinociception produced by analgesics and the adjuvants, it has not been fully examined yet how the conduction inhibition differs in extent among their drugs. We investigated the effects of various antidepressants used as analgesic adjuvants on compound action potentials (CAPs) recorded from the frog sciatic nerve by using the air-gap method. The results were compared with those of the other adjuvants that were reported previously...
December 1, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29197738/efficacy-and-safety-of-levomilnacipran-vilazodone-and-vortioxetine-compared-with-other-second-generation-antidepressants-for-major-depressive-disorder-in-adults-a-systematic-review-and-network-meta-analysis
#8
REVIEW
Gernot Wagner, Marie-Therese Schultes, Viktoria Titscher, Birgit Teufer, Irma Klerings, Gerald Gartlehner
BACKGROUND: Second-generation antidepressants dominate the medical management of major depressive disorder (MDD). Levomilnacipran, vilazodone and vortioxetine are the latest therapeutic options approved for the treatment of MDD. This systematic review aims to compare the benefits and harms of vilazodone, levomilnacipran, and vortioxetine with one another and other second-generation antidepressants. METHODS: We searched electronic databases up to September 2017 and reviewed reference lists and pharmaceutical dossiers to detect published and unpublished studies...
November 16, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29197345/perioperative-duloxetine-and-etoricoxibto-improve-postoperative-pain-after-lumbar-laminectomy-a-randomized-double-blind-controlled-study
#9
Josef Zekry Attia, Haidy Salah Mansour
BACKGROUND: Duloxetine, Etoricoxib and opioid are of the commonly administered drugs in Lumbar laminectomy. The aim of this study is to assess the effect of perioperative use of Duloxetine in combination with Etoricoxib on postoperative pain and opioid requirements. METHODS: One hundred twenty patients with ASA physical status were enrolled with age between 18 and 70 years. Patients were divided randomly into four groups of 30 patients: group P received placebo, group E received etoricoxib 120 mg, group D received duloxetine 60 mg and group D/E received duloxetine 60 mg capsules and etoricoxib 120 mg; 1 h before surgery and 24 h after...
December 2, 2017: BMC Anesthesiology
https://www.readbyqxmd.com/read/29189543/acute-angle-closure-glaucoma-associated-with-aripiprazole-in-the-setting-of-plateau-iris-configuration
#10
Elizabeth Shen, Sarah Farukhi, Mason Schmutz, Sameh Mosaed
PURPOSE OF THE STUDY: To report a novel case of drug-induced angle-closure from aripiprazole (Abilify), an atypical antipsychotic, and propose a mechanism for this association. METHODS/RESULTS: We report a case of a 45 year-old Caucasian woman who presented in subacute angle closure two months after initiating aripiprazole 5 mg daily for depression. This patient reported no prior ocular history and had been on longstanding duloxetine (Cymbalta) 60 mg daily for over ten years prior to starting aripiprazole...
November 17, 2017: Journal of Glaucoma
https://www.readbyqxmd.com/read/29172829/formulation-and-optimization-of-duloxetine-hydrochloride-buccal-films-in-vitro-and-in-vivo-evaluation
#11
Amr Mostafa El Sharawy, Marwa Hassan Shukr, Ahmed Hassen Elshafeey
Duloxetine hydrochloride (DH) is a serotonin-norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism. This study aims to develop DH buccoadhesive films to improve its bioavailability. DH buccoadhesive films were prepared adopting the solvent casting method using hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA). The prepared films were evaluated for weight uniformity, drug content, surface pH, swelling index, mucoadhesion strength and drug release percentages...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/29170185/dysosmia-and-dysgeusia-associated-with-duloxetine
#12
Katsuyuki Yoshida, Takahiko Fukuchi, Hitoshi Sugawara
Common adverse effects of serotonin-norepinephrine reuptake inhibitors are nausea, dry mouth, dizziness and headache. We describe the case of a patient with dysosmia and subsequent dysgeusia associated with duloxetine. A 68-year-old Japanese woman with a history of type 1 diabetes mellitus, hypertension, insomnia and reflux esophagitis presented to a local hospital with bilateral leg pain; she was treated with duloxetine. However, after 4 weeks, she sensed rotten egg smell, experienced nausea and vomiting and was admitted to our hospital...
November 23, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29163055/study-of-sex-differences-in-duloxetine-efficacy-for-depression-in-transgenic-mouse-models
#13
Yong Xu, Lei Ma, Wei Jiang, Yuhong Li, Gang Wang, Rena Li
Clinical evidences show sex differences in risk of developing depressive disorders as well as effect of antidepressants in depression treatment. However, whether such a sex-dependent risk of depression and efficacy of antidepressants is dependent on endogenous estrogen level remain elusive. The aim of this study is to explore the molecular mechanisms of sex differences in antidepressant duloxetine. In the present study, we used genetic knockout or overexpression estrogen-synthesizing enzyme aromatase (Ar) gene as models for endogenous estrogen deficiency and elevation endogenous estrogen, respectively, to examine the anti-depressive efficacy of duloxetine in males and females by force swimming test (FST)...
2017: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/29162053/duloxetine-induced-rapid-eye-movement-sleep-behavior-disorder-a-case-report
#14
Lu Tan, Junying Zhou, Linghui Yang, Rong Ren, Ye Zhang, Taomei Li, Xiangdong Tang
BACKGROUND: Tricyclic antidepressants and selective serotonin reuptake inhibitors have been reported to induce the symptoms of rapid eye movement (REM) sleep behavior disorder (RBD) or to exacerbate REM sleep without atonia. With this case report, we found an association between typical RBD and duloxetine, a serotonin-noradrenaline reuptake inhibitor. CASE PRESENTATION: We present a case of a 62-year-old woman who experienced enactment behaviors with violent dreams that were associated with increased tonic or phasic chin electromyography activity during REM sleep after treated with duloxetine...
November 21, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29154157/efficacy-of-antidepressants-on-measures-of-workplace-functioning-in-major-depressive-disorder-a-systematic-review
#15
REVIEW
Yena Lee, Joshua D Rosenblat, JungGoo Lee, Nicole E Carmona, Mehala Subramaniapillai, Margarita Shekotikhina, Rodrigo B Mansur, Elisa Brietzke, Jae-Hon Lee, Roger C Ho, Samantha J Yim, Roger S McIntyre
INTRODUCTION: Work-related disability and productivity loss in Major Depressive Disorder (MDD) are critical determinants of patient quality of life and contribute significantly to the human and economic costs of MDD. Notwithstanding the return to work and pre-morbid levels of functioning as a critical therapeutic objective among individuals with MDD, it is unclear whether antidepressant treatment significantly and reliably improves measures of workplace functioning. Herein, we investigate to what extent antidepressant treatment improves workplace functioning among adults with MDD...
November 7, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29142460/efficacy-and-safety-of-duloxetine-in-chinese-breast-cancer-patients-with-paclitaxel-induced-peripheral-neuropathy
#16
Jiani Wang, Qing Li, Binghe Xu, Tongtong Zhang, Shanshan Chen, Yang Luo
Objective: Chemotherapy with paclitaxel is associated with significant neurotoxicity that may offset patients' quality of life and therapeutic benefits. This prospective, non-randomized control study evaluated the efficacy and safety of an antidepressant drug, duloxetine, at 30 or 60 mg/d, in the treatment of paclitaxel-induced peripheral neuropathy (PIPN) in Chinese breast cancer patients. Methods: A total of 102 patients with a median age of 50 (range, 25-60) years, treated in the Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, between November 2014 and January 2017 were finally enrolled...
October 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/29137046/multiple-adverse-drug-reactions-and-genetic-polymorphism-testing-a-case-report-with-negative-result
#17
Ana Lucía Arellano, Marta Martin-Subero, Mar Monerris, Adrián LLerena, Magí Farré, Eva Montané
RATIONALE: Defects in drug metabolic pathways could explain why some patients have a history of multiple adverse drug reactions (ADR); therefore we aimed to analyze genetic polymorphisms in a patient with multiple ADR related to drugs with a common hepatic metabolic pathway through CYP2D6. PATIENT CONCERNS: We report a patient with psychosis and hypertension related to amitriptyline, tramadol, and duloxetine within a 2-year period. INTERVENTIONS AND OUTCOMES: A pharmacogenetic test was performed to assess the causative role of the CYP2D6 enzyme, but did not demonstrate a metabolic deficiency...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29136387/randomized-multicenter-placebo-controlled-clinical-trial-of-duloxetine-versus-placebo-for-aromatase-inhibitor-associated-arthralgias-in-early-stage-breast-cancer-swog-s1202
#18
N Lynn Henry, Joseph M Unger, Anne F Schott, Louis Fehrenbacher, Patrick J Flynn, Debra M Prow, Carl W Sharer, Gary V Burton, Charles S Kuzma, Anna Moseley, Danika L Lew, Michael J Fisch, Carol M Moinpour, Dawn L Hershman, James L Wade
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved for treatment of multiple chronic pain disorders. We hypothesized that treatment of AIMSS with duloxetine would improve average joint pain compared with placebo. Methods This randomized, double-blind, phase III trial included AI-treated postmenopausal women with early-stage breast cancer and who had average joint pain score of ≥ 4 out of 10 that developed or worsened since AI therapy initiation...
November 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29134401/duloxetine-protects-human-neuroblastoma-cells-from-oxidative-stress-induced-cell-death-through-akt-nrf-2-ho-1-pathway
#19
Daiane Fátima Engel, Jade de Oliveira, Vicente Lieberknecht, Ana Lucia Severo Rodrigues, Andreza Fabro de Bem, Nelson Horácio Gabilan
The contribution of oxidative stress to the pathophysiology of depression has been described in numerous studies. Particularly, an increased production of reactive oxygen species (ROS) caused by mitochondrial dysfunction can lead to neuronal cell death. Human neuroblastoma SH-SY5Y cells were used to investigate the neuroprotective effect of the antidepressant duloxetine against rotenone-induced oxidative stress. SH-SY5Y cells were pretreated with duloxetine (1-5 µM) for 24 h followed by a 24-h rotenone exposure (10 µM)...
November 13, 2017: Neurochemical Research
https://www.readbyqxmd.com/read/29121279/clinical-and-preclinical-perspectives-on-chemotherapy-induced-peripheral-neuropathy-cipn-a-narrative-review
#20
S J L Flatters, P M Dougherty, L A Colvin
This review provides an update on the current clinical and preclinical understanding of chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome includes a review of its assessment, diagnosis and treatment. CIPN is caused by several widely-used chemotherapeutics including paclitaxel, oxaliplatin, bortezomib. Severe CIPN may require dose reduction, or cessation, of chemotherapy, impacting on patient survival. While CIPN often resolves after chemotherapy, around 30% of patients will have persistent problems, impacting on function and quality of life...
October 1, 2017: British Journal of Anaesthesia
keyword
keyword
23003
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"